颖泰生物
(833819)
| 流通市值：41.07亿 | | | 总市值：41.68亿 |
| 流通股本：12.08亿 | | | 总股本：12.26亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,374,078,857.91 | 5,868,305,351.83 | 4,395,196,061.07 | 2,954,829,186.08 |
| 营业收入 | 1,374,078,857.91 | 5,868,305,351.83 | 4,395,196,061.07 | 2,954,829,186.08 |
| 二、营业总成本 | 1,400,108,915.88 | 5,646,981,763.18 | 4,223,675,945.88 | 2,781,739,616.93 |
| 营业成本 | 1,207,431,189.61 | 4,863,913,295.04 | 3,610,512,551.91 | 2,374,866,297.31 |
| 税金及附加 | 7,941,159.13 | 32,527,355.4 | 24,422,724.66 | 15,968,467.22 |
| 销售费用 | 17,825,104.12 | 99,781,586.38 | 74,643,354.75 | 50,200,644.84 |
| 管理费用 | 92,501,130.18 | 363,365,088.74 | 285,961,846.71 | 187,942,022.6 |
| 研发费用 | 38,485,848.65 | 166,540,895.64 | 140,297,646.87 | 93,956,787.89 |
| 财务费用 | 35,924,484.19 | 120,853,541.98 | 87,837,820.98 | 58,805,397.07 |
| 其中:利息费用 | 43,726,074.16 | 184,351,298.64 | 133,099,420.95 | 88,006,077.1 |
| 其中:利息收入 | 5,428,015.77 | 33,694,377.81 | 20,967,734.44 | 14,705,350.02 |
| 加:公允价值变动收益 | -747,635.04 | -802,444.18 | -343,144.57 | -4,206,751.94 |
| 加:投资收益 | -3,193,953.22 | -70,571,926.79 | 6,599,904.69 | 1,771,360.93 |
| 资产处置收益 | 192,168.54 | 21,883,529.25 | 2,845,901.86 | -214,963.26 |
| 资产减值损失(新) | -52,112.44 | -87,258,225.06 | -1,033,648.36 | -1,033,648.36 |
| 信用减值损失(新) | -301,827.41 | 13,233,146.5 | 6,273,735.6 | 4,967,189.55 |
| 其他收益 | 5,282,301.1 | 68,928,803.25 | 29,201,837.01 | 21,054,358.27 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -24,851,116.44 | 166,736,471.62 | 215,064,701.42 | 195,427,114.34 |
| 加:营业外收入 | 1,436,845.64 | 8,051,218.01 | 5,042,828.16 | 5,092,459.74 |
| 减:营业外支出 | 1,965,005.39 | 11,568,939.96 | 7,618,393.22 | 6,365,275.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -25,379,276.19 | 163,218,749.67 | 212,489,136.36 | 194,154,298.25 |
| 减:所得税费用 | 5,983,243.93 | 72,044,510.73 | 66,389,365.03 | 47,614,662.96 |
| 六、净利润 | -31,362,520.12 | 91,174,238.94 | 146,099,771.33 | 146,539,635.29 |
| 持续经营净利润 | -31,362,520.12 | 91,174,238.94 | 146,099,771.33 | 146,539,635.29 |
| 归属于母公司股东的净利润 | -29,764,161.3 | 95,683,463.98 | 153,501,845.12 | 150,131,634.59 |
| 少数股东损益 | -1,598,358.82 | -4,509,225.04 | -7,402,073.79 | -3,591,999.3 |
| (一)基本每股收益 | -0.02 | 0.08 | 0.13 | 0.12 |
| (二)稀释每股收益 | -0.02 | 0.08 | 0.13 | 0.12 |
| 八、其他综合收益 | -8,113,453.1 | 19,036,007.53 | 59,895,948.14 | 88,277,328.27 |
| 归属于母公司股东的其他综合收益 | -8,113,453.1 | 19,036,007.53 | 59,895,948.14 | 88,277,328.27 |
| 九、综合收益总额 | -39,475,973.22 | 110,210,246.47 | 205,995,719.47 | 234,816,963.56 |
| 归属于母公司股东的综合收益总额 | -37,877,614.4 | 114,719,471.51 | 213,397,793.26 | 238,408,962.86 |
| 归属于少数股东的综合收益总额 | -1,598,358.82 | -4,509,225.04 | -7,402,073.79 | -3,591,999.3 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-27 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |